who are OUR FIRST patients?

High-risk populations for cancer

Our initial focus is to transform the surveillance of liver cancer in high-risk populations - the fastest growing cause of cancer related deaths.

For example, 10 million people in the United States and Europe are at high risk of developing liver cancer each year, often due to a pre-existing medical condition such as cirrhosis. These patients are enrolled in surveillance programmes for early liver cancer detection, primarily through ultrasound imaging, which is recommended twice yearly due to the fast progression of liver cancer. 

However, detection rates remain low because ultrasound lacks sufficient sensitivity, particularly in overweight individuals. Additionally, poor adherence to the programme is common, as it requires a separate appointment from routine blood tests and is hindered by the known limitations of ultrasound. 

learn more

WHAT DO WE ANALYZE?

Extracellular vesicles (EVs) 
in blood

Extracellular vesicles (EVs) are small, membrane-bound particles continuously released by living cells throughout their lifespan. The cargo of EVs are not exported randomly; they reflect the health status of their parental cells and are enriched with bioactive components involved in critical cellular functions. EVs serve as convenient 'windows' into cellular processes, generally transmitting specific intercellular messages regionally and across organs. 

When a blood sample is taken, it contains billions of these EVs including hundreds of thousands derived from specific organs like the liver. For more visual explanations, please watch our 3D video.

learn more

HOW DO WE ANALYZE?

Pioneering dynamic biopsy

Mursla Bio's transformative biopsy platform is non-invasive and provides a dynamic view of the biological processes within a specific organ or tissue. This approach combines the high accuracy and disease sub-typing precision of tissue biopsies with the simplicity of liquid biopsy sample collection. 

This dynamic biopsy is made possible by leveraging extracellular vesicle (EV) science and an innovative approach called extracellular omics, alongside Mursla Bio’s pioneering technologies. These technologies include: (i) Organ-specific EV isolation, (ii) AI-enabled multi-omics biomarker discovery workflow, and (iii) scalable EV multi-omics assays for clinical use.

learn more

OUR news

Mursla Bio enters the US market with strategic expansion

Mursla Bio launches US strategy to bring its novel liquid biopsy tests – based on extracellular vesicle technology – to patients
NEXOS

Mursla Bio presents breakthrough liquid biopsy technology for extracellular vesicles in Cell Press

Novel and scalable analysis of extracellular vesicles sub-types detailed in Cell Press’ iScience

Mursla Bio helps shape the standardisation of EV-based liquid biopsy for clinical use

Mursla Bio participates in a unique global initiative to standardise the clinical use of novel EV-based biomarkers for liquid biopsy

Our Partners